Skip to main content

Advertisement

SpringerLink
Log in

HIV Resistance Testing: Methods, Utility, and Limitations

  • Current Issues
  • Published:
Molecular Diagnosis Aims and scope Submit manuscript

Abstract

Widespread use of combination antiretroviral therapy for HIV has led to increased incidence of HIV resistance and a need for antiretroviral resistance testing to optimize therapeutic choices. Antiretroviral resistance analysis is performed using either genotypic or phenotypic assays. Genotypic assays identify resistance-associated mutations in the HIV genome. They are faster and less technically demanding than phenotypic assays; however, the associations between mutations and resistance patterns are often complicated, making interpretation difficult. Phenotypic assays directly measure the ability of antiviral compounds to inhibit replication of patient-derived virus. Phenotypic assays provide results that are easier to interpret; however, there is little data that relates the degree of resistance detected in phenotypic assays to patient clinical response. Despite limitations, the improved therapeutic outcome of therapies guided by resistance testing is leading to incorporation of resistance testing into the standard of care for HIV treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. US Department of Health and Human Services and the Henry J. Kaiser Family Foundation: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.hivatis.org/trtgdlns.html. Accessed: January 28, 2000

  2. Palella FJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338: 853–860

    Article  PubMed  Google Scholar 

  3. Lee CG, Gottesman MM, Cardarelli CO, et al.: HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594–3601

    Article  PubMed  CAS  Google Scholar 

  4. Hoetelmans RM, Reijers MH, Weverling GJ, et al.: The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998;12: F111–F115

    Article  PubMed  CAS  Google Scholar 

  5. Descamps D, Flandre P, Calvez V, et al.: Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege Agence National de Recherches sur le SIDA 072 Study Team. JAMA 2000;283: 205–211

    Article  PubMed  CAS  Google Scholar 

  6. Young B, Johnson S, Bahktiari M, et al.: Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis 1998; 178: 1497–1501

    Article  PubMed  CAS  Google Scholar 

  7. Miller V, Phillips A, Rottmann C, et al.: Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: Association with therapy failure. J Infect Dis 1998;177: 1521–1532

    Article  PubMed  CAS  Google Scholar 

  8. Zolopa AR, Shafer RW, Warford A, et al.: HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999;131: 813–821

    PubMed  CAS  Google Scholar 

  9. Deeks SG, Hellmann NS, Grant RM, et al.: Novel four-drug salvage type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999;179: 1375–1381

    Article  PubMed  CAS  Google Scholar 

  10. Lorenzi P, Opravil M, Hirschel B, et al.: Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999;13: F17–F21

    Article  PubMed  CAS  Google Scholar 

  11. Durant J, Clevenbergh P, Halfon P, et al.: Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 1999;353: 2195–2199

    Article  PubMed  CAS  Google Scholar 

  12. Clevenbergh P, Durant J, Halfon P, et al.: Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: Week 48 follow-up. Antiviral Ther 2000;5: 65–70

    CAS  Google Scholar 

  13. Baxter JD, Mayers DL, Wentworth DN, et al.: A randomized study of antiretroviral management based on plasma genotype antiretroviral resistance testing (GART) in patients failing therapy. AIDS 2000;14: F83–F93

    Article  PubMed  CAS  Google Scholar 

  14. Cohen C, Hunts S, Sension M, et al.: Phenotypic resistance testing significantly improves response to therapy: Final analysis of a randomized trial (VIRA 3001). Antiviral Ther 2000;5: 67 (suppl 3, abstr 84)

    Google Scholar 

  15. Mansky LM, Temin HM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from the purified reverse transcriptase. J Virol 1995;69: 5087–5094

    PubMed  CAS  Google Scholar 

  16. Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373: 123–126

    Article  PubMed  CAS  Google Scholar 

  17. Mulder J, McKinney N, Christopherson C, et al.: Rapid and simple PCR assays for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. J Clin Microbiol 1994;32: 292–300

    PubMed  CAS  Google Scholar 

  18. Stuyver L, Wyseur A, Rombout A, et al.: Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997;41: 284–291

    PubMed  CAS  Google Scholar 

  19. Schoolmeester A, Nuytten A, Verhelst R, et al.: A line probe assay (LiPA) for the detection of drug selected mutations in the HIV-1 protease gene. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24–27, 1998, San Diego, CA (abstr I-109)

  20. Hirsch M, Brun-Vezinet F, D’Aquila R, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 2000;283: 2417–2426

    Article  PubMed  CAS  Google Scholar 

  21. Koch N, Yahi N, Colson P, et al.: Genetic polymorphism near HIV-1 reverse transcriptase resistance-associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis. J Virol Methods 1999;80: 25–31

    Article  PubMed  CAS  Google Scholar 

  22. Puchhammer-Stockl E, Schmied B, Mandl CW, et al.: Comparison of line probe assays (LiPA) and sequence analysis for detection of HIV-1 drug resistance. J Med Virol 1999;57: 283–289

    Article  PubMed  CAS  Google Scholar 

  23. Fodor SP, Read JL, Pirrung MC, et al.: Light-directed, spatially addressable parallel chemical synthesis. Science 1993;251: 767–773

    Article  Google Scholar 

  24. Pease AC, Solas DM, Sullivian EJ, et al.: Lightgenerated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A 1994; 91: 5022–5026

    Article  PubMed  CAS  Google Scholar 

  25. Kozal MJ, Shah N, Shen N, et al.: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2: 753–759

    Article  PubMed  CAS  Google Scholar 

  26. Vahey M, Nau ME, Barrick S, et al.: Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type I clades and viral isolates with length polymorphisms. J Clin Microbiol 1999;37: 2533–2537

    PubMed  CAS  Google Scholar 

  27. Hanna GJ, Johnson VA, Kuritzkes DR, et al.: Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 2000;38: 2715–2721

    PubMed  CAS  Google Scholar 

  28. Nersesian RC, Fong DM, Kolmodin RM, et al.: Development of a microarray-based HIV-1 drug resistance/genotyping assay. Seventh Conference on Retroviruses and Opportunistic Infections, January 30–February 2, 2000, San Francisco, CA (abstr 794)

  29. Schuurman R, Demeter L, Reichelderfer P, et al.: Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999;37: 2291–2296

    PubMed  CAS  Google Scholar 

  30. Shapiro J, Winters MA, Lawrence J, Merigan TC: Clinical cross-resistance between HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS 1999;13: 359–365

    Article  Google Scholar 

  31. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70: 8270–8276

    PubMed  CAS  Google Scholar 

  32. Rose RE, Gong YF, Gertok JA, et al.: Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci U S A 1996;93: 1648–1653

    Article  PubMed  CAS  Google Scholar 

  33. Kemp SD, Shi C, Bloor S, et al.: A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J Virol 1998;72: 5093–5098

    PubMed  CAS  Google Scholar 

  34. Nijhuis M, Schuurman R, de Jong D, et al.: Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 1997;176: 398–405

    Article  PubMed  CAS  Google Scholar 

  35. Gaschen BK, Rose PP, Foley BF, et el.: HIV database and analysis projects at Los Alamos: An overview. Seventh Conference on Retroviruses and Opportunistic Infections, January 30–February 2, 2000, San Francisco, CA (abstr 164)

  36. Larder B, De Vroey V, Dehertogh P, et al.: Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database. Antiviral Ther 1999;4: 41 (suppl 1, abstr 59)

    Google Scholar 

  37. Japour AJ, Mayers DL, Johnson VA, et al.: Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother 1993;37: 1095–1101

    Article  PubMed  CAS  Google Scholar 

  38. Kellam P, Larder BA: Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994;38: 23–30

    Article  PubMed  CAS  Google Scholar 

  39. Petropoulos CJ, Parkin NT, Limoli KL, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44: 920–928

    Article  PubMed  CAS  Google Scholar 

  40. Hertogs K, de Bethune MP, Miller V, et al.: A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42: 269–276

    Article  PubMed  CAS  Google Scholar 

  41. Garraffo R, Durant J, Clevenbergh P, et al.: Relevance of protease inhibitor plasma levels in patients treated with genotypic adapted therapy: Pharmacological data from the Viradapt study. Antiviral Ther 1999;4: 75 (suppl 1, abstr 109)

    Google Scholar 

  42. Merry C, Back D, Barry M, et al.: Therapeutic drug monitoring (TDM) of protease inhibitors (PIs): What to measure and when. Seventh Conference on Retroviruses and Opportunistic Infections, January 30–February 2, 2000, San Francisco, CA (abstr 104)

  43. Conway B: Development of drug resistance in patients receiving combinations of zidovudine, didanosine, and nevirapine. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26–29, 1999, San Francisco, CA (abstr 436)

  44. Hsu A, Granneman GR, Cao G, et al.: Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998;63: 453–464

    Article  PubMed  CAS  Google Scholar 

  45. Zhang YM, Imamichi H, Imamichi T, et al.: Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997;71: 6662–6670

    PubMed  CAS  Google Scholar 

  46. Maeda Y, Venzon DJ, Mitsuya H, et al.: Altered drug sensitivity, fitness and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 1998;177: 1207–1213

    Article  PubMed  CAS  Google Scholar 

  47. Devereux HL, Youle M, Johnson MA, Loveday C: Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13:F123–F127

    Article  PubMed  CAS  Google Scholar 

  48. Mulder J, Resnick R, Saget B, et al.: A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: Enhanced sensitivity. J Clin Microbiol 1997;35: 1278–1280

    PubMed  CAS  Google Scholar 

  49. Shafer RW, Warford A, Winters MA, et al.: Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1 infected individuals. J Virol Methods 2000;86: 143–153

    Article  PubMed  CAS  Google Scholar 

  50. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2: 760–766

    Article  PubMed  CAS  Google Scholar 

  51. Patik AK, Zhang M, Hertogs K, et al.: Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program. International Workshop on HIV Drug Resistance and Treatment Strategies, June 24–27, 1998, Lake Maggiore, Italy (abstr 57)

  52. Hammer S, Demeter L, DeGruttola V, et al: Relationship of phenotypic and genotypic resistance profiles to virological outcome in a trial of abacavir, nelfinavir, efavirenz and adefovir dipivoxil in patients with virological failure receiving indinavir (ACTG 372). Antiviral Ther 1999;4: 45 (suppl 1, abstr 64)

    Google Scholar 

  53. Call S, Westfall A, Cloud G, et al.: Predictive value of HIV phenotypic susceptibility testing in a clinical cohort. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26–29, 1999, San Francisco, CA (abstr LB-17)

  54. Harrigan PR, Montaner JS, Hogg RS, et al.: Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting. International Workshop on HIV Drug Resistance and Treatment Strategies, June 24–27, 1998, Lake Maggiore, Italy (abstr 55)

  55. Hecht FM, Grant RM, Petropoulos CJ, et al.: Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. N Engl J Med 1998;339: 307–311

    Article  PubMed  CAS  Google Scholar 

  56. Imrie A, Beveridge A, Genn W, et al.: Transmission of human immunodeficiency virus type-1 resistant to nevirapine and zidovudine. Sydney primary HIV infection study group. J Infect Dis 1997;175: 1502–1506

    Article  PubMed  CAS  Google Scholar 

  57. Eron JJ, Vernazza PL, Johnston DM, et al.: Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: Implications for transmission. AIDS 1998;12:F181–F189

    Article  PubMed  CAS  Google Scholar 

  58. Little SJ, Daar ES, D’Aquila RT, et al.: Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999;282: 1142–1149

    Article  PubMed  CAS  Google Scholar 

  59. Boden D, Hurley A, Zhang L, et al.: HIV-1 drug resistance in newly infected individuals. JAMA 1999;282: 1135–1141

    Article  PubMed  CAS  Google Scholar 

  60. Little SJ: Transmission and prevalence of HIV resistance among treatment-naive subjects. Antiviral Ther 2000;5: 33–40

    CAS  Google Scholar 

  61. Food and Drug Administration Antiviral Advisory Committee: Meeting Minutes, November 2–3, 1999, Gaithersburg, MD. Available at: http://www.fda.gov/ohrms/dockets/ac/acmenu.htm.Accessed: Feb. 2000

Download references

Author information

Authors and Affiliations

  1. CMBP, LabCorp, 1912 Alexander Dr, Research Triangle Park, North Carolina, 27709

    Timothy M. Alcorn PhD (Director of Infectious Disease) & Hawazin Faruki DrPH

Authors
  1. Timothy M. Alcorn PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hawazin Faruki DrPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy M. Alcorn PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alcorn, T.M., Faruki, H. HIV Resistance Testing: Methods, Utility, and Limitations. Molecular Diagnosis 5, 159–168 (2000). https://doi.org/10.1007/BF03262072

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262072

Keywords

Search

Navigation